Why Attend
Animal Health Innovation Latin America connects animal health start-ups in Latin America with opportunities for financial investment and strategic partnerships.
Last year forced businesses to adapt, the way the region operates is evolving towards a more digitally- focused world. From better monitoring of animals enabling better and earlier treatment, to facilitating closer ties between industry stakeholders, Latin America holds a wealth of opportunity for businesses in both petcare and livestock.
At Animal Health Innovation Latin America we work closely with the animal health community in order to be able to provide a platform for building partnerships and making critical connections.
Speakers
Carlos Alberto Kuada
Matias de Juan
Klaus Hellmann
Flávia De Marco Almeida
Luiz Luccas
Delair Angelo Bolis
Luiz Xavier Royas
Marcio Waldman
Felipe Cunha
Felipe Diz
Mauricio Salvador
Flavia Reis
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
Kleber Gomes
Byron Silva
PROFILE:
- Veterinary with expertise for over 35 years in veterinary products segment working for local and global players. Previous experience in several areas of veterinary industry: vaccine production, QC, R&D, product manager, technical assistance and regulatory affairs.
- Support for technical and regulatory affairs for new and existing business.
- Support for development of new businesses in Brazil for global players.
Maria Aparecida Melo Luspa, MSc.
Gustavo Osorio
Gustavo Osorio is a Mexican Veterinarian who started his successful career in the Animal Health Industry as sales representative for companion animal products with Pfizer Animal Health, where he gained commercial experience working with distributors and third party sales forces.
During his tenure in Pfizer Animal Health, Gustavo held different position of increased responsibility. He worked as Technical Manager for Companion Animal being responsible for technical trainings for the team as well as speaker in different events. He was promoted to Sales Force Manager, working in a sales efficiency project while starting his incursion in marketing, this movement allowed him to move to the Marketing Manager position.
In 2006, Gustavo joined Bayer Animal Health as Marketing Manager for Companion Animals. During his 8 year tenure, he contributed to the evolution of the business unit by introducing new lines of products while managing the growth of the companion animals portfolio.
From 2014 to 2018, Gustavo was Influencer Marketing Manager for Eukanuba at Mars. This position allowed him to better understand the motivations and habits of pet owners as well as learn from the pet food industry and gain a new set of skills oriented at the commercial models applied in this segment.
Since 2018, Gustavo is the Commercial Manager for Mexico, Central America and the Caribbean at Dechra Brovel, the Mexican subsidiary of Dechra. He is focused on the transformation of the company structure from a family owned company to an international corporation, successfully launching specialized products such as Vetoryl and Zycortal while maintaining the growth of the generic products business. He is also developing and strengthening his team to address future challenges.
Kieran Gartlan
Angélica Patarroyo Vargas
Arthur Gabriel da Silva
Bruna Nunes Marsiglio Sarout
Carla Berl
Ricardo Nassar
Ricardo Nassar has graduated in Business Administration by FAAP, an important University in Brazil. He is one of the co-founder at Cobasi – o shopping do seu animal since 1885.
Together with his brothers, has created the concept of big pet shop in Brazil and has turned Cobasi into a reference in the Brazilian pet market. Cobasi is currently sales leader, with more 100 stores and e-commerce.
Prof. Newton C. Frateschi
Prof. Newton C. Frateschi is the Executive Director of the Inova-UNICAMP: Unicamp Innovation Agency. He was the director of the "Gleb Wataghin" Physics Institute (IFGW), University of Campinas – UNICAMP - Brazil from 2014 to 2017; the deputy director of this institute from 2010 to 2014. He was the director of the Center for Semiconductor Components and Nanotechnologies – UNICAMP from 2005 to 2010. From 2001 to 2003, he worked as a senior optoelectronic designer at T-Networks Inc., Pennsylvania, USA, in the advanced photonic device technology group. He obtained his Master’s and PhD in Electrical Engineering from the University of Southern California and his bachelor’s and Master’s degree in Physics from the IFGW - UNICAMP. He is a Brazilian National Research and Development Council (CNPq – Brasil) research fellow leading the device Research Laboratory (LPD – IFGW - UNICAMP) and the author and coauthor of over 100 scientific papers and several international patents primarily in the areas of optoelectronics and photonics.
Eduardo Carlos de Gosztonyi Abecia
Clóvis De Oliveira
Carla Freitas
Aidan Connolly
Who Attends?
Headline Partner
Zoetis
Website: https://animalhealthlatam.com/events/animal-health-latam-2021
Website: www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Associate Partner
IDEXX
Website: www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
Gold Digital Innovation Partners
Clinglobal
Website: https://www.clinglobal.com/
CLINGLOBAL is an Animal Health Services company established during 2016 in Mauritius acting as a contract holding and centralised service provider for the ever expanding “Clin” group of companies.
Our unique business model allows the animal health industry and community to benefit from our simplified contracting solutions by having a customizable all-inclusive approach and the delivery of animal health research projects and services.
Klifovet
Website: www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
MSD Saúde Animal
Website: https://www.msd-saude-animal.com.br/
Please visit our website for more information.Silver Digital Innovation Partners
Media Partners
MOTIVAR
Website: www.motivar.com.ar
MOTIVAR es el primer periódico íntegramente dedicado al análisis del sector veterinario argentino. Tal es así que desde hace años nos encontramos directamente involucrados en la problemática de un mercado en el cual nuestro nombre representa objetividad y confianza para más de 5.000 lectores de todo el país, los cuales reciben mensualmente nuestra publicación de manera gratuita y personalizada.
En la actualidad, MOTIVAR es distribuido en distintas esferas:
Sector Público
- Ministerio de la Producción (Técnicos).
- Secretaría de Agricultura, Ganadería, Pesca y Alimentación de la Nación. (Funcionarios, técnicos, asesores y prensa).
- SENASA (Presidencia, Consejo de Administración, Direcciones nacionales y prensa).
Sector Industrial
- Más de 200 laboratorios de todo el país (Presidencia, gerencia, director técnico, ventas, marketing, compras y asesores).
- Veterinarios y Productores.
- Productores nacionales (Asociaciones, federaciones y fundaciones ligadas a bovinos, porcinos, avicultura, ovinos, equinos, etc).
- Más de 3.000 veterinarios de todo el país, Colegios y Consejos profesionales).
Sector Académico
- Facultades de Ciencias Veterinarias de todas las Universidades del país (autoridades, docentes, prensa, investigación y desarrollo y bibliotecas).
- Sectores de Investigación y Desarrollo.
- Centros públicos y privados (INTA, INTI, INCAM, CEVAN, etc).
- Proveedores de la industria.
Abiquifi
Website: https://www.abiquifi.org.br/
A Abiquifi – Associação Brasileira da Indústria de Insumos Farmacêuticos foi fundada em 1983 com a razão social Abiquifi – Associação Brasileira da Indústria Farmoquímica. Desde 2010, para melhor representar as empresas que se dedicam à produção de adjuvantes farmacotécnicos e de insumos farmacêuticos não ativos, a associação já adicionara um “i” ao seu nome fantasia. Mudança consolidada em 2018. A inclusão de mais um “i” no seu nome abrilhanta os mais de 35 anos de trabalho contínuo e profícuo da Abiquifi em prol de uma indústria de insumos farmacêuticos brasileira forte e representa, também, o início de uma nova era no apoio de empresas produtoras de farmoquímicos e insumos farmacêuticos ativos e não ativos.
Biominas
Website: https://biominas.org.br/?lang=en
Through its three business areas, Biominas Brasil has a solution to offer, at any stage of business development in the sector, from accelerating ideas to expanding business. It is also a reference in consulting and relationship with the national and international life sciences ecosystem.
Biominas Brasil was born in 1990 from the initiative of a group of companies that aimed to promote the life sciences sector in Minas Gerais. Originally with this focus, working to stimulate the creation of new companies and support existing ones, the institution, over time, expanded its field of action and its geographic scope. It currently has a varied portfolio of services and customers spread across the country and in different parts of the world.
AgriBrasilis - Inside agribusiness Independent
Website: http://agribrasilis.com/
AgriBrasilis is an agribusiness portal of Brazil and Latin America. We provide information to our readers, directly from the source and independently. Top news, references and trends on agribusiness, connecting you to the scenarios of the largest agricultural pole in the world through articles, interviews, research and visits to professionals and institutions in the different sectors of agribusiness.
The Agenda
Download the 2021 agenda.
Fill in this form to access the 2021 agenda. We need some information to know where to send the file and how to address our email to you.
Download the Agenda
Global Advisory Board
Marc Prikazsky
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Aaron Schacht
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Author:
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
George Gunn
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket prices increase in
Become a Partner
Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.
Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.
Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.
Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]
Press Partnerships
Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:
- Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
- Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
- Provide one free press pass to attend
- Distribute promotional materials at the conference
If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:
Jessica Parry
Senior Marketing Manager
T: +44 (0)203 696 2920
E: [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
